A follow-up study indicated that targeted killing of TNFR2-expressing tumor cells and Tregs using TNFR2 antagonistic antibodies is therapeutic in advanced Sézary syndrome, a rare form of cutaneous T-cell lymphoma that is often refractory to treatment (Torrey et al., 2019). Here, TNFRSF1B is linked to primary cutaneous T-cell non-Hodgkin lymphoma.